Sophiris Bio Inc. Applies for Voluntary Delisting From TSX

Published: Nov 06, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO & VANCOUVER, British Columbia--(BUSINESS WIRE)--Sophiris Bio Inc. (NASDAQ:SPHS) (TSX: SHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), today announced that it has applied for voluntary delisting of its common shares from the Toronto Stock Exchange (“TSX”). Sophiris’ common shares are currently listed for trading on the NASDAQ Global Market and the TSX. After delisting from the TSX, the Company’s shares will continue to trade on NASDAQ under the symbol “SPHS”.

Help employers find you! Check out all the jobs and post your resume.

Back to news